SCHEMBL1665283

SCHEMBL1665283

CC(C)(C)OC(=O)N1CCN(c2cc(F)c(F)c(CO)c2F)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 7/20 0.48
HTT P42858 2/20 0.44
MAPT P10636 4/20 0.43
ALDH1A1 P00352 3/20 0.43
LMNA P02545 1/20 0.43
DPP4 P27487 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
SMARCA2 P51531 1/20 0.41
SMARCA4 P51532 1/20 0.41
PBRM1 Q86U86 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
PDK2 Q15119 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP3A5 P20815 1/20 0.40
KDM4E B2RXH2 1/20 0.40
POLB P06746 1/20 0.40
GAA P10253 1/20 0.40
HPGD P15428 1/20 0.40
ALOX15 P16050 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1663320 0.89 GPR119 (0.47) GPR119HTTMAPTALDH1A1LMNA
SCHEMBL27885743 0.87 GPR119 (0.46) GPR119HTTMAPTALDH1A1LMNA
SCHEMBL1662688 0.85 GPR119 (0.48) GPR119HTTMAPTALDH1A1LMNA
SCHEMBL1665397 0.81 GPR119 (0.44) GPR119HTTMAPTALDH1A1LMNA
SCHEMBL20139942 0.80 GPR119 (0.45) GPR119HTTMAPTALDH1A1LMNA
SCHEMBL671635 0.79 LMNA (0.47) GPR119HTTMAPTALDH1A1LMNA
SCHEMBL20140111 0.79 MAPT (0.54) GPR119HTTMAPTALDH1A1LMNA
SCHEMBL21937028 0.78 MAPT (0.51) GPR119HTTMAPTALDH1A1LMNA
SCHEMBL27885748 0.78 GPR119 (0.42) GPR119HTTMAPTALDH1A1LMNA
SCHEMBL8220970 0.78 SMN1; SMN2 (0.47) GPR119HTTMAPTALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9242987-B2 Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors CELLZOME LIMITED (GB) 2016-01-26 US disclosed
US-20120252779-A1 HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS CELLZOME LIMITED (GB) 2012-10-04 US disclosed
EP-2491039-A1 HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS Cellzome Limited (GB) 2012-08-29 EP disclosed
WO-2011048082-A1 HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS CELLZOME LIMITED (GB) 2011-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120252779-A1 HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS JAK1, JAK3, JAK2 GPR119 3906/4885HTT 4097/4885MAPT 4393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.